|
On September 9 2004 the President and CEO of Dendreon said in an interview: "We have seen a significant and robust immune response of all patients that received APC8024. It is essentially the same high data that we saw in our Provenge platform again showing that we can expand the platform into other antigen targets. We believe that this is a very promising program for the Company. It's been very well tolerated and we'll be moving it into a significant Phase 2 study in the short term." Transcript 090904ad.789FD (Fair Disclosure) Wire Copyright 2004 CCBN Inc.Source: Lexis-Nexis.
|